Millipore is targeting protein manufacturers with a new chromatography resin that, the firm claims, offers flexibility and high throughput with a small manufacturing footprint.
The product, named ProRes-S media, was developed in collaboration with Dow Chemical as a mono-dispersed polymethacrylate strong cation exchange resin designed with the production of monoclonal antibodies (MAbs) in mind.
Paul Chapman, VP of downstream processing unit, said: “Combining Millipore's expertise in purification with Dow's extensive experience in ion-exchange resins technology allows us to offer biopharmaceutical manufacturers a substantially expanded chromatography solution."
Millipore also claim the resin offers a broader operating window over a wider range of conductivities than available medias and is optimized for resolving difficult impurities.
Merck takeover approved
In other news, European regulators have approved Merck KGaA's proposed $7.2bn (EUR5.6bn) acquisition of Millipore. The deal, announced in March , is part of the German drugmaker's effort to add bioprocessing and bioscience expertise to its chemical and active pharmaceutical ingredient (API) production business.